Ignite Creation Date:
2025-12-25 @ 4:24 AM
Ignite Modification Date:
2025-12-26 @ 3:27 AM
Study NCT ID:
NCT05818020
Status:
COMPLETED
Last Update Posted:
2024-06-26
First Post:
2023-03-22
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Multidisciplinary Integrated Platform for a Technological Innvovative Approach to Oncotherapies
Sponsor:
National Cancer Institute, Naples
Organization:
Study Overview
Official Title:
Fighting Cancer Resistance: Multidisciplinary Integrated Platform for a Technological Innvovative Approach to Oncotherapies
Status:
COMPLETED
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is multicentric, observational, and retro- prospective study.
Detailed Description:
The project aims to develop a regional platform for innovative disease treatment oncology. In particular, an integrated platform will be created with several complementary skills among them, which have as their common objective to increase knowledge and the possibilities of surgery for certain types of cancer.
The actions implemented in this project will be as follows:
* Improvement of primary and secondary prevention strategies with precocious diagnostic devices;
* Optimization of therapeutic treatments by custom drawing of the scheme therapeutic;
* Improved therapeutic efficacy for high social impact resistant neoplasms development of innovative treatments such as personalized therapeutic vaccines and small molecules;
* Improving patient compliance and quality of life accompanied by less need of hospitalization of the patient himself with consequent decongestion of hospital admissions;
* Reduction of health costs as a result of early diagnosis and new therapies more effective and less invasive;
* Increasing regional health and technological attractiveness in a high bio-medical sector social and health impact.
The actions implemented in this project will be as follows:
* Improvement of primary and secondary prevention strategies with precocious diagnostic devices;
* Optimization of therapeutic treatments by custom drawing of the scheme therapeutic;
* Improved therapeutic efficacy for high social impact resistant neoplasms development of innovative treatments such as personalized therapeutic vaccines and small molecules;
* Improving patient compliance and quality of life accompanied by less need of hospitalization of the patient himself with consequent decongestion of hospital admissions;
* Reduction of health costs as a result of early diagnosis and new therapies more effective and less invasive;
* Increasing regional health and technological attractiveness in a high bio-medical sector social and health impact.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 40/19oss | OTHER | IRCCS I.N.T. "G. Pascale" | View |